Recent studies have focused on the intersection of GLP-1|GIP|glucagon receptor activator therapies and DA neurotransmission. While GCGR agonists are increasingly employed for addressing type 2 diabetes mellitus, their emerging impacts on reinforcement circuits, specifically mediated by dopamine networks, are receiving significant attention. This ar